<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[Bristol-Myers Squibb Co. | Company News & Executive Profiles - BMY | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/bristol-myers+squibb+co..html?i=11]]></link>
	<description><![CDATA[Latest company news & analysis, recent events, stock quotes, earning call transcripts, with profiles and descriptions of top business executives for Bristol-Myers Squibb Co.]]></description>
	<s:counts start="0" returned="10" found="693" />
	<language>en-us</language>
	<item>
		<title><![CDATA[Bristol-Myers Squibb Sees Perfect Timing to Divest Huge Mead Johnson Nutrition Stake]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F175393-bristol-myers-squibb-sees-perfect-timing-to-divest-huge-mead-johnson-nutrition-stake%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[The Burrill Report submits:  Bristol-Myers Squibb BMY will sell its last non-biopharmaceutical holding, a majority stake in Mead Johnson Nutrition MJN, the company said. The pediatric nutrition company produces Enfamil baby formula and is a leading supplier of children&#8217;s nutritional products globally. Bristol-Myers&#8217; move, part of a wider healthcare...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Thu, 26 Nov 2009 12:16:58 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/the+burrill+report.html"><![CDATA[The Burrill Report]]></category>
		<category domain="http://resources.bnet.com/topic/bristol-myers+squibb+co..html"><![CDATA[Bristol-Myers Squibb Co.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">BMY</category>
		<category domain="tickers">BMY</category>
	</item>
	<item>
		<title><![CDATA[Bristol-Myers Receives Approval for Autism Drug]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F174850-bristol-myers-receives-approval-for-autism-drug%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Zacks.com submits:   Recently, Bristol-Myers Squibb Co. BMY received approval from the U.S. Food and Drug Administration FDA to market Abilify aripiprazole for the treatment of irritability in pediatric patients having autistic disorder. Abilify can be used to treat children aged 6 to 17 years for symptoms of aggression...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Mon, 23 Nov 2009 08:11:46 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/zacks.com.html"><![CDATA[Zacks.com]]></category>
		<category domain="http://resources.bnet.com/topic/bristol-myers+squibb+co..html"><![CDATA[Bristol-Myers Squibb Co.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">BMY</category>
		<category domain="tickers">BMY</category>
	</item>
	<item>
		<title><![CDATA[Bristol-Myers Squibb Co. Q3 2009 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14055_23-355577.html]]></link>
		<description><![CDATA[ Question-and-Answer SessionOperator Operator Instructions We'll go first to John Boris at Citi. John Boris - Citi Jim, first question just has to do with 2013 and beyond and how you're thinking about the growth profile of the company. Operationally, the company is running very well. A lot of pipeline...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Thu, 22 Oct 2009 12:50:20 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/growth.html"><![CDATA[Growth]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/citigroup+inc..html"><![CDATA[Citigroup Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/bristol-myers+squibb+co..html"><![CDATA[Bristol-Myers Squibb Co.]]></category>
		<category domain="http://resources.bnet.com/topic/managerial+accounting.html"><![CDATA[Managerial Accounting]]></category>
		<category domain="http://resources.bnet.com/topic/strategy.html"><![CDATA[Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/management.html"><![CDATA[Management]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">BMY</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">C</category>
		<category domain="tickers">BMY,C</category>
	</item>
	<item>
		<title><![CDATA[Bristol-Myers Squibb Q3: Beats by a Penny]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F168151-bristol-myers-squibb-q3-beats-by-a-penny%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Zacks.com submits:   Thursday, Bristol-Myers Squibb Company BMY reported  third quarter earnings of 52 cents per share, beating the Zacks Consensus  Estimate by a penny. The company reported earnings of 45 cents in the year-ago  period.Net sales for the quarter came in at $5,487 million, against...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Thu, 22 Oct 2009 08:15:40 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/zacks.com.html"><![CDATA[Zacks.com]]></category>
		<category domain="http://resources.bnet.com/topic/bristol-myers+squibb+co..html"><![CDATA[Bristol-Myers Squibb Co.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">BMY</category>
		<category domain="tickers">BMY</category>
	</item>
	<item>
		<title><![CDATA[Earnings Preview: Bristol-Myers Squibb]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F167917-earnings-preview-bristol-myers-squibb%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Bristol-Myers Squibb BMY is expected to report Q3  earnings Thursday, October 22 before the market open with a conference call  scheduled for 10:30am ET.  Guidance Analysts are looking for EPS of 51c on revenue of  $5.52B. The consensus range is 48c-54c for EPS, and $5.43B-$5.68B for...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Wed, 21 Oct 2009 11:35:42 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/theflyonthewall.com.html"><![CDATA[theflyonthewall.com]]></category>
		<category domain="http://resources.bnet.com/topic/bristol-myers+squibb+co..html"><![CDATA[Bristol-Myers Squibb Co.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">BMY</category>
		<category domain="tickers">BMY</category>
	</item>
	<item>
		<title><![CDATA[Bristol Myers Scores with Diabetes Drug]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F164871-bristol-myers-scores-with-diabetes-drug%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Zacks.com submits:   On Friday, Bristol-Myers Squibb Co. BMY announced that its diabetes drug dapagliflozin, in combination with metformin (commonly prescribed oral anti-diabetic medication), significantly reduced levels of glycosylated haemoglobin which is an indication of glucose concentration in the blood in type II diabetes patients as compared to placebo...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Mon, 05 Oct 2009 10:53:03 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/zacks.com.html"><![CDATA[Zacks.com]]></category>
		<category domain="http://resources.bnet.com/topic/bristol-myers+squibb+co..html"><![CDATA[Bristol-Myers Squibb Co.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">BMY</category>
		<category domain="tickers">BMY</category>
	</item>
	<item>
		<title><![CDATA[FDA Reviewing Bristol-Myers Squibb Biologic Transplant Drug]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F160350-fda-reviewing-bristol-myers-squibb-biologic-transplant-drug%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Zacks.com submits:   Last week, Bristol-Myers Squibb Company BMY announced the acceptance of a biologic license application BLA for belatacept by the U.S. Food and Drug Administration FDA. The candidate is in late-stage development for treating kidney transplant patients. The agency has set May 1, 2010, as the Prescription...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Tue, 08 Sep 2009 02:03:57 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/zacks.com.html"><![CDATA[Zacks.com]]></category>
		<category domain="http://resources.bnet.com/topic/bristol-myers+squibb+co..html"><![CDATA[Bristol-Myers Squibb Co.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">BMY</category>
		<category domain="tickers">BMY</category>
	</item>
	<item>
		<title><![CDATA[Big French Pharma Moves to Distance Itself from U.S. Healthcare Protests]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F156762-big-french-pharma-moves-to-distance-itself-from-u-s-healthcare-protests%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Vincent Fernando submits:  In an almost satirical twist to the healthcare debate, it turns out that Big French Pharma, in the form of Sanofi-Aventis SNY, is now linked to anti-Obamacare protests via lobbying firm DLA Piper.   DLA ex-employee Dick Armey is chairman of Freedomworks, a pressure group...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Tue, 18 Aug 2009 06:34:04 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/vincent+fernando.html"><![CDATA[Vincent Fernando]]></category>
		<category domain="http://resources.bnet.com/topic/bristol-myers+squibb+co..html"><![CDATA[Bristol-Myers Squibb Co.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">BMY</category>
		<category domain="tickers">BMY</category>
	</item>
	<item>
		<title><![CDATA[Bristol-Myers Gets Its Antibody Deal at Last]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F151078-bristol-myers-gets-its-antibody-deal-at-last%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[EP Vantage submits: On the same day that Eli Lilly LLY was talking up the commercial prospects of pipeline candidates acquired through its $6.5bn purchase of ImClone Systems last year, a deal which hijacked Bristol-Myers Squibb&#8217;s BMY plans to get its hands on an antibody technology platform, BMS has finally...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Fri, 24 Jul 2009 01:44:17 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/ep+vantage.html"><![CDATA[EP Vantage]]></category>
		<category domain="http://resources.bnet.com/topic/bristol-myers+squibb+co..html"><![CDATA[Bristol-Myers Squibb Co.]]></category>
		<category domain="http://resources.bnet.com/topic/eli+lilly+%2526+co..html"><![CDATA[Eli Lilly & Co.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">BMY</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">LLY</category>
		<category domain="tickers">BMY,LLY</category>
	</item>
	<item>
		<title><![CDATA[Bristol-Myers Squibb Company Q2 2009 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14055_23-324041.html]]></link>
		<description><![CDATA[ Question-and-Answer SessionOperator Thank you. Operator instructions Our first question comes from Mr. Jami Rubin with Goldman Sachs. Jami Rubin - Goldman Sachs Hi. Mrs. Jami Rubin. Anyway, very good quarter. I wanted to ask you Jim as long as we have you on the call to talk sort of...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Thu, 23 Jul 2009 12:12:34 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/germany.html"><![CDATA[Germany]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/bristol-myers+squibb+co..html"><![CDATA[Bristol-Myers Squibb Co.]]></category>
		<category domain="http://resources.bnet.com/topic/plavix.html"><![CDATA[Plavix]]></category>
		<category domain="http://resources.bnet.com/topic/marketing+research.html"><![CDATA[Marketing Research]]></category>
		<category domain="http://resources.bnet.com/topic/sales+strategy.html"><![CDATA[Sales Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/mergers+%2526+acquisitions.html"><![CDATA[Mergers & Acquisitions]]></category>
		<category domain="http://resources.bnet.com/topic/marketing.html"><![CDATA[Marketing]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[Sales]]></category>
		<category domain="http://resources.bnet.com/topic/investment.html"><![CDATA[Investment]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">BMY</category>
		<category domain="tickers">BMY</category>
	</item>
</channel>
</rss>
